Economic assessments of low molecular weight heparin in venous thromboembolism

References

• Koopman MW Prandoni F Provella F et al Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N. Engl. J Merl 334(11), 682— 687 (1996).
   Google Scholar
• Levine M, Gent M, Hirsh J et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N. Engl. Merl 334(11), 677–681 (1996).
   Google Scholar
• White RII. The epidemiology of venous thromboembolism. Circulation7(23 Suppl. 1), 14–18 (2003).
   Google Scholar
• •Coherent review of the epidemiology literature systematically summarizing the available evidence, and explaining the limitations of the various approaches adopted by the studies.
   Google Scholar
• Silverstein MD, Heft JA, Mohr DN et al Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern. Med. 158(6), 585–593 (1998).
   Google Scholar
• Murin S, Romano PS, White RII. Comparison of outcomes after hospitalization for deep venous thrombosisor pulmonary embolism. Thmmb. Haemost. 88(3), 407–414 (2002).
   Google Scholar
• Kahn SR, Solymoss S, Lamping DL, Abenhaim L. Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life. j Gen. Intern. Med. 15(6), 425–429 (2000).
   Google Scholar
• •Reviews the literature on the incidence of postphlebitis syndrome, risk factors and treatment, and the impact on the patient's quality of life. The authors provide insightful comments on the limitations of the data available.
   Google Scholar
• Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern. Med. 160(19), 2926–2932 (2000).
   Google Scholar
• van den Belt AG, Bossuyt PM, Prins MET, Gallus AS, Buller HR for the TASMAN Study Group. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis — an economic evaluation. TASMAN Study Group. Thromb. Haemost. 79(2), 259–263 (1998).
   Google Scholar
• O'Brien B, Levine M, Willan A et al Economic evaluation of outpatient treatment with low molecular weight heparin for proximal vein thrombosis. Anh Intern. Med. 159(19), 2298–2304 (1999).
   Google Scholar
• Pearson SD, Blair R, Halpert A, Eddy E, McKean S. An outpatient program to treat deep venous thrombosis with low molecular weight heparin. Effective Gun. Prac. 2, 210–217 (1999).
   Google Scholar
• Boccalon H, Elias A, Chale JJ, Cadene A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low molecular weight heparin: the Vascular Midi-Pyrenees study. Arch Intern. Med. 160(12), 1769–1773 (2000).
   Google Scholar
• Smith BJ, Weeldey JS, Pilotto L, Howe T, Beven R. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin. Intern. Merl 32(1–2), 29–34 (2002).
   Google Scholar
• Lapidus L, Borretzen J, Fahlen M et al. Home treatment of deep vein thrombosis. An outpatient treatment model with once-daily injection of low molecular weight heparin (tinzaparin) in 555 patients. Pathophysiol 1-Lemost. Thromb. 32 (2), 59–66 (2002).
   Google Scholar
• Spyropoulos AC, Hurley JS, Ciesla GN, de Lissovoy G. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 122(1), 108–114 (2002).
   PubMed Web of Science ®Google Scholar
• Groce JB III. Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program. Phaimacotherapy18(6 Pt 3), S175—S180 (1998).
   Google Scholar
• Huse DM, Cummins G, Taylor DC, Russell MW Outpatient treatment of venous thromboembolism with low molecular weight heparin: an economic evaluation. Am. j Manag. Cam 8 (1 Suppl.), S10—S16 (2002).
   Google Scholar
• de Lissovoy G, Yusen RD, Spiro TE, Krupski WC, Champion AH, Sorensen SV. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Arch. Intern Med. 160(20), 3160–3165 (2000).
   Google Scholar
• Leong WA. Outpatient deep vein thrombosis treatment models. Phaimacotherapy 18(6 Pt 3), S170—S174 (1998).
   Google Scholar
• Boucher M, Rodger M, Johnson JA, Tierney M. Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care center: a cost-minimization analysis. Pharmacotherapy 23(3), 301–309 (2003).
   Google Scholar
• Wells PS, Kovacs MJ, Bormanis J et al. Expanding eligibility for outpatient treatment of deep vein thrombosis and pulmonary embolism with low molecular weight heparin. Arch Intern Med. 158, 1809–1812 (1998).
   PubMed Web of Science ®Google Scholar
• Segal JB, Bolger DT, Jenckes MW et al Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety and costs. Am. j Med. 115(4), 298–308 (2003).
   PubMed Web of Science ®Google Scholar
• •Recent review of the evidence on the efficacy and safety of treating deep vein thrombosis (DVT) in the an out- versus inpatient setting and the cost-effectiveness of low molecular weight heparin (LMWH) or unfractionated heparin.
   Google Scholar
• O'Brien JA, Caro JJ. Direct medical costs of managing deep venous thrombosis according to the occurrence of complications. PharmacoEconomics 20 (9), 603–615 (2002).
   Google Scholar
• •Detailed costing study of managing DVT and its complications, including estimates for the cost of treatment in various inpatient and outpatient settings, this paper provides recent and comprehensive US cost estimates. Cost estimates from this study were used in an economic evaluation of tinzaparin versus unfractionated heparin (UFH) for the treatment of DVT
   Google Scholar
• Rodger M, Bredeson C, Wells P, Beck J, Kearns B, Huebsch LB. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in the treatment of deep vein thrombosis. Can. j Med. Assoc. 59(8), 931–938 (1998).
   Google Scholar
• Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low molecular weight heparins compared to unfractionated heparin for treatment of acute deep vein thrombosis. A cost-effectiveness analysis. Ann Intern. Med. 130(10), 789–799 (1999).
   Google Scholar
• •First pharrnacoeconomic model to compare long-term outcomes for the treatment of DVT with UFH and LMWH. Previous modeling efforts had limited their time horizon to the duration of short-term clinical trials.
   Google Scholar
• Estrada CA, Mansfield CJ, Heudebert GR. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. j Gen. Intern Med. 15 (2), 108–115 (2000).
   Google Scholar
• Caro JJ, Getsios D, Caro I, O'Brien JA. Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. PharmacoEconomics 20 (9), 593–602 (2002).
   PubMedGoogle Scholar
• Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl. I Med. 326(15), 975–982 (1992).
   Google Scholar
• Prandoni P, Lensing AWA, Cogo A et al The long-term clinical course of the deep venous thrombosis. Ann. Intern. Med. 125, 1–7 (1997).
   Google Scholar
• Bergqvist D, Hendteg S, Johansen J, Persson U, Odegaard K. Cost of long-term complications of deep-venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann. Intern. Med. 126,454-457 (1997).
   Google Scholar
• Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep vein thrombosis. j A. Med. Inform. Assoc. 4,89–102 (1997).
   Google Scholar
• McCart GM, Kayser SR Therapeutic equivalency of low-molecular-weight heparins. Ann. Phaimacother 36(6),1042–1057(2002).
   Google Scholar
• Michalis LK, Katsouras CS, Papamichael N, Adamides K, Naka KK, Goudevenos J, Sideris DA. Enoxaparin versus tinzaparin in nonST-segment elevation acute coronary syndromes: the EVET trial. Am. Hear t 146(2), 304–310 (2003).
   Google Scholar
• Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch. Intern. Med. 160,181–188 (2000).
   Google Scholar
• Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis. A meta-analysis of randomized, controlled trials. Ann. Intern. Med. 130(10), 800–809 (1999).
   Google Scholar
• Ageno W, Steidl L, Marchesi C et al Selecting patients for home treatment of deep vein thrombosis: the problem of cancer. Haematologica 87 (3), 286–291 (2002) .
   Google Scholar
• Dunn AS, Schechter C, Gotlin A et al. Outpatient treatment of deep venous thrombosis in diverse inner-city patients. Am. Merl 110(6), 458–462 (2001).
   Google Scholar
• Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with dalteparin. Thromb. Haemost. 83(2), 209–211 (2000) .
   PubMed Web of Science ®Google Scholar
• Heit JA, Mohr DN, Silverstein MD et al Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 160(6), 761–768 (2000).
   Google Scholar
• Ganz DA, Glynn RJ, Mogun H, Knight EL, Bohn RL, Avorn J. Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism. j Gen Intern. Med. 15 (11), 776–781 (2000).
   Google Scholar
• Heit JA, Silverstein MD, Mohr DN, Petterson TM, OFallon WM, Melton III U. Predictors of survival after deep vein thrombosis and pulmonary embolism. A population-based, cohort study. Arch Intern. Med. 158,445–453 (1999).
   Google Scholar
• Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, Selfa S. Home treatment of deep venous thrombosis with low molecular weight heparin: long-term incidence of recurrent venous thromboembolism. Am. .1. Remota 67 (1), 10–14 (2001).
   Google Scholar
• Spyropoulos AC. Outpatient-based treatment protocols in the management of venous thromboembolic disease. Aim Man. Care 6(20 Suppl), S1034—S1044 (2000).
   Google Scholar
• Huisman MV on behalf of the THRIVE treatment study investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran for acute deep vein thrombosis with or without pulmonary embolism. XLYCongress of the International Society on Thrombosis and Haemostasir, Birmingham, UK. July 12–18 (2003).
   Google Scholar
• Van Oers MHJ on behalf of the The Matisse Investigators. Fondaparinux (Arixtra) in comparison to (low molecular weight) heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism — The Matisse Clinical Outcome Studies. 44th Annual Meeting of the American Society of Hematology, PA, USA. December 7–10. (2002).
   Google Scholar
• Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low molecular weight heparin: outcome of therapy and health economy aspects. Haemostasis 28\(Suppl. 3), 8–16 (1998).
   Google Scholar